Double-Punch therapy tested for Tough-to-Treat blood cancer
NCT ID NCT06365671
Summary
This study is testing a two-part treatment for patients with B-cell lymphoma that has come back or hasn't responded to standard treatments. First, patients receive a high-dose chemotherapy and their own stem cell transplant. Then, three days later, they receive an infusion of specially engineered immune cells (CAR-T cells) designed to hunt and kill the cancer. The goal is to see if this combination is safe and effective for controlling this aggressive form of cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.